Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)
Sponsor: Merck Sharp & Dohme LLC
This PHASE3 trial investigates Non-small Cell Lung Cancer and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 20 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
20 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Nov 2022 — Nov 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 15 earlier versions
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — May 2020 [monthly]
Active Not Recruiting PHASE3
-
Nov 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Apr 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — May 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2017 — Feb 2018 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.